UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

|
|



Form 10-K/A



Amendment No. 1



|
|

(Mark One)



|x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ------------------------------------------------------------------------------------



For the fiscal year ended December 31,
2014

or



|o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------



For the transition period from                 
to

Commission file number: 001-35867

|
|



Chimerix, Inc.

(Exact Name of Registrant as Specified
in its Charter)

|
|



|Delaware                                                               |  | 33-0903395                                  
|---------------------------------------------------------------------- |  | --------------------------------------------
|(State or Other Jurisdiction of
        Incorporation or Organization) |  | (I.R.S. Employer
        Identification No.)
|                                                                       | 
|2505 Meridian Parkway, Suite 340
        Durham, North Carolina        |  | 27713                                       
|(Address of Principal Executive Offices)                               |  | (Zip Code)                                  



(919) 806-1074

(Registrant’s Telephone Number,
Including Area Code)

Securities registered pursuant to Section 12(b)
of the Act:



|Title of Each Class                      |  | Name of Each Exchange on Which Registered
|---------------------------------------- |  | -----------------------------------------
|Common Stock, par value $0.001 per share |  | The NASDAQ Stock Market LLC              



Securities registered pursuant to Section 12(g)
of the Act: None

|
|



Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes   x
    No   o



Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes   o
    No   x



Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.    Yes   x
    No   o



Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files).    Yes   x
    No   o



Indicate by check mark if disclosure of delinquent
filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s
knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment
to this Form 10-K. x



Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of
“large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act:



|Large accelerated filer   o |  | Accelerated filer   x |  | Non-accelerated filer   o |  | Smaller reporting company   o
|--------------------------- |  | --------------------- |  | ------------------------- |  | -----------------------------



Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).    Yes  
o     No   x



The aggregate market value of the voting and non-voting common
equity held by non-affiliates of the registrant based upon the closing price of its Common Stock on The Nasdaq Global Market on
June 30, 2014 was $443,167,025.*



The number of outstanding shares of the registrant’s
common stock, par value $0.001 per share, as of February 24, 2015 was 41,086,040.



DOCUMENTS INCORPORATED BY REFERENCE



Portions of the registrant’s proxy statement to be filed
with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2015 Annual Meeting
of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form
10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end
of the registrant’s fiscal year ended December 31, 2014.



*    Based on a closing price of $21.94
per share on June 30, 2014. Excludes 15,205,282 shares of the registrant's Common Stock held by executive officers, directors
and any stockholders whose ownership exceeds 5% of registrant's Common Stock outstanding at June 30, 2014. Exclusion of such
shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the
direction of the management or policies of the registrant or that such person is controlled by or under common control with the
registrant.













Explanatory
Note



Chimerix, Inc. (the “Company”)
is filing this Amendment No. 1 (the “Amendment”) to its Annual Report on Form 10-K for the
year ended December 31, 2014, as filed with the Securities and Exchange Commission on March 6, 2015 (the “Original
Filing”), solely to correct clerical errors on the cover page of the Original Filing and in Exhibits 31.1 and 31.2
attached to the Original Filing.



Except as described above, no other changes
have been made to the Original Filing. Accordingly, this Amendment does not reflect events occurring after the filing of the Original
Filing or modify or update those disclosures affected by subsequent events. Information not affected by this Amendment remains
unchanged and reflects the disclosures made at the time the Original Filing was filed. Therefore, this Amendment should be read
in conjunction with any documents incorporated by reference therein and the Company’s filings made with the Securities and
Exchange Commission subsequent to the Original Filing.











PART IV



| | ITEM 15. | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
| | -------- | ------------------------------------------



1. Financial Statements. No financial statements are
filed with this Amendment. These items were included as part of the Original Filing.



2. Financial Statement Schedules. None.



3. Exhibits.The exhibits listed in the Original Filing
are required by Item 601 of Regulation S-K. A list of the exhibits filed with this Amendment is provided below.



|Exhibit
        Number |  | Description of Document                                                                                                                                                                                 
|---------------------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|31.1                   |  | Certification of Principal Executive Officer, pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|31.2                   |  | Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.













SIGNATURES



Pursuant to the requirements of Section 13
or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 1 to its Annual Report on Form
10-K to be signed on its behalf by the undersigned, thereunto duly authorized.





|                                 | Chimerix, Inc. |                                    
|-------------------------------- | -------------- | -----------------------------------
|                                 |                |                                    
|Date:             March 27, 2015 | By:            | /s/    M. Michelle Berrey          
|                                 |                | M. Michelle Berrey, M.D., MPH      
|                                 |                | President & Chief Executive Officer
|                                 |                |                                    





Pursuant to the requirements of the Securities
Exchange Act of 1934, this Amendment No. 1 to Annual Report on Form 10-K has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.



|Signature                           |  | Title                                            |  | Date          
|----------------------------------- |  | ------------------------------------------------ |  | --------------
|                                    |  |                                                  |  |               
|/s/    M. Michelle Berrey           |  | President, Chief Executive Officer and Director  |  | March 27, 2015
|M. Michelle Berrey, MD, MPH         |  | (Principal Executive Officer)                    |  |               
|                                    |  |                                                  |  |               
|/s/    Timothy W. Trost             |  | Senior Vice President, Chief Financial Officer   |  | March 27, 2015
|Timothy W. Trost                    |  | and Corporate Secretary (Principal Financial and |  |               
|                                    |  | Accounting Officer)                              |  |               
|                                    |  |                                                  |  |               
|/s/    Ernest Mario*                |  |                                                  |  |               
|Ernest Mario, PhD                   |  | Chairman of the Board of Directors               |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/    James M. Daly*               |  |                                                  |  |               
|James M. Daly                       |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/    Martha J. Demski*            |  |                                                  |  |               
|Martha J. Demski                    |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/    Catherine L. Gilliss*        |  |                                                  |  |               
|Catherine L. Gilliss, PhD, RN, FAAN |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/    John M. Leonard*             |  |                                                  |  |               
|John M. Leonard, MD                 |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/    C. Patrick Machado*          |  |                                                  |  |               
|C. Patrick Machado                  |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/    James Niedel*                |  |                                                  |  |               
|James Niedel, MD, PhD               |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/   Ronald C. Renaud. Jr*         |  |                                                  |  |               
|Ronald C. Renaud, Jr                |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/    Lisa Ricciardi*              |  |                                                  |  |               
|Lisa Ricciardi                      |  | Director                                         |  | March 27, 2015
|                                    |  |                                                  |  |               
|/s/ Timothy J. Wollaeger*           |  |                                                  |  |               
|Timothy J. Wollaeger                |  | Director                                         |  | March 27, 2015





* Pursuant to Power of Attorney



| | By: | /s/ M. Michelle Berrey
| | --- | ----------------------

M. Michelle Berrey, MD, MPH